Adrenal cancer

1. Abiven G, Coste J, Groussin L et al. Clinical and biological features in the prognosis of adrenal cortical carcinoma. Poor outcome of cortisol secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 2006; 91: 2650–2655.

2. Allolio B, Hahner S, Weissmann D et al. Management of adrenocortical carcinoma. Clin Endocrinol 2004; 60: 273–287.

3. Arnaldi G, Freddi S, Mancini T et al. Transforming growth factor beta1: implications in adrenocortical tumorigenesis. Endocr Res 2000; 26: 905–910.

4. Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am J Surg Pathol 2002; 26: 1612–1619.

5. Baudin E, Docao C, Gicquel C et al. Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma. Ann Oncol 2002; 13: 1806–1809.

6. Bernini GP, Moretti A, Bonadio AG et al. Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab 2002; 87: 4961–4965.

7. Berruti A, Terzolo M, Pia A et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Cancer 1998; 83: 2194–2200.

8. Berruti A, Terzolo M, Sperone P et al. Etoposide, doxorubicin and cisplatin plus Op’DDD in the treatment of advanced adrenal cortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 2005; 12: 657–666.

9. Beuschlein F, Reincke M, Karl M et al. Clonal composition of human adrenocortical neoplasm. Cancer Res 1994; 54: 4927–4932.

10. Blakker H, Sutter C, Kadmon M et al. Analysis of somatic APC mutations in rare extracolonic tumors of patients with familial adenomatous polyposis coli. Genes Chromosomes Cancer 2004; 41: 93–98.

11. Boulle N, Logie A, Gicquel C et al. Increased levels of insulin‑like growth factor II (IGF‑II) and IGF‑binding protein‑2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998; 83: 1713–1720.

12. Bossis I, Stratakis CA. Minireview: Prkar1a: normal and abnormal functions. Endocrinology 2004; 145: 5452–5458.

13. Caoili EM, Korobkin M, Francis IR et al. Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 2002; 222: 629–633.

14. de Baere T, Dufaux J, Roche A et al. Circulatory alterations induced by intra-arterial injection of iodized oil and emulsions of iodized oil and Doxorubicin: Experimental study. Radiology 1995; 194: 165–170.

15. de Fraipont F, El Atifi M, Cherradi N et al. Gene expression profiling of human adrenocortical tumors using cDNA microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005; 90: 1819–1829.

16. Fallo F, Pilon C, Barzon L et al. Paclitaxel is an effective antiproliferative agent on the human NCI-H295 adrenocortical carcinoma cell line. Chemotherapy 1998; 44: 129–134.

17. Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 2007; 11: 13–28.

18. Fryšák Z, Záťura F, Benýšek L et al. Incidentalomy nadledvin. Klinické zkušenosti. Vnitř Lék 1998; 44: 538–540.

19. Gao ZH, Suppola S, Liu J et al. Association of H19 promoter methylation with the expression of H19 and IGF‑II genes in adrenocortical tumors. J Clin Endocrinol Metab 2002; 87: 1170–1176.

20. Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long‑term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 2001; 61: 6762–6767.

21. Gonzales RJ, Shapiro S, Sarlis N et al. Laparoscopic resection of adrenal cortical carcinoma: a cautionary note. Surgery 2005; 138: 1078–1085.

22. Gross MG, Shapiro B, Francis IR. Scintigrafic evaluation of clinically silent adrenal masses. J Nucl Med 1994; 35: 1145–1152.

23. Grumbach MM, Biller BMK, Braunstein GD et al. Management of the clinically inaparent adrenal mass („incidentaloma“). Ann Intern Med 2003; 138: 424–429.

24. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in consecutive series of 96 patients. Br J Cancer 1994; 69: 947–951.

25. Hisada M, Garber JE, Fung CY et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90: 606–611.

26. Hussain HK, Korobkin M. MR imaging of the adrenal glands. Magn Reson Imaging Clin N Am 2004; 12: 515–544.

27. Chiche L, Dousset B, Kieffer E et al. Adrenal cortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature. Surgery 2006; 139: 15–27.

28. Icard P, Goudet P, Charpenay C et al. Adrenocortical carcinomas: surgical trends and results of a 253-patients series from the French Association of Endocrine Surgeons study group. World J Surg 2001; 25: 891–897.

29. Jorda M, De MB, Nadji M. Calretinin and inhibin are useful in separating adrenocortical neoplasms from pheochromocytomas. Appl Immunohistochem Mol Morphol 2002; 10: 67–80.

30. Khan TS, Sundin A, Juhlin C et al. Vincristine, cisplatin, teniposide, and cyclophosphamide combination in the treatment of recurrent or metastatic adrenal cortical carcinoma. Med Oncol 2004; 21: 167–177.

31. Kloos RT, Gross RT, Francis IR et al. Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460–484.

32. Kršek M, Matějovská H. Diferenciální diagnóza incidentalomů nadledvin a úloha zobrazovacích metod. Vnitř Lék 2002; 48: 409–415.

33. Kršek M. Incidentalomy nadledvin. Vnitř Lék 2007; 53: 821–825.

34. Lack EE. Recommendations for the reporting of tumors of the adrenal cortex and medulla. Association of Directors of Anatomic and Surgical Pathology. Virchows Arch 1999; 435: 87–91.

35. Lam WW, Hatada I, Ohishi S et al. Analysis of germline CDKN1C (p57kip2) mutations in familial and sporadic Beckwith-Wiedemann syndrome (BWS) provides a novel genotype-phenotype correlation. J Med Genet 1999; 36: 518–523.

36. Leboulleux S, Dromain C, Bonniaud G et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 2005; 91: 920–925.

37. Libé R, Gicquel C, Bertagna X et al. Molecular genetics of adrenal cortical carcinoma. 13–23. In: Bertagna X. Adrenal cancer. France, Montrouge: John Libbey Eurotext 2006, 133 s.

38. Luton JP, Cerdas S, Billaud L et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990; 322: 1195–1201.

39. Luton JP, Martinez M, Coste J et al. Outcome in patients with adrenal incidentaloma selected for surgery: an analysis of 88 cases investigated in a single clinical center. Eur J Endocrinol 2000; 143: 111–117.

40. MacFarlane DA. Cancer of the adrenal cortex; natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958; 23: 155–186.

41. McGahan J, Browning P, Brock J et al. Hepatic ablation using radiofrequency electrocautery. Invest Radiol 1990; 25: 267–270.

42. Nelson AA, Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2-bis-(parachlorphenyl)-1,1-dichlorethane (DDD). Arch Pathol 1949; 48: 387.

43. Newell‑Price J, Bertagna X, Grossman AB et al. Cushing’s syndrome. Lancet 2006; 367: 1605–1617.

44. Pan CC, Chen PC, Tsay SH et al. Dif­ferential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol 2005; 13: 347–352.

45. Paulsen SD, Nghiem HV, Korobkin M et al. Changing role of imaging-guided percutaneous biopsy of adrenal masses: evaluation of 50 adrenal biopsies. Am J Roentgenol 2004; 182: 1033–1037.

46. Reincke M, Beuschlein F, Menig G et al. Localization and expression of adrenocorticotropic hormone receptor mRNA in normal and neoplastic human adrenal cortex. J Endocrinol 1998; 156: 415–423.

47. Roche A, Girish BV, de Baere T et al. Trans‑catheter arterial chemoembolisation as first‑line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003; 13: 136–140.

48. Ross NS, Aron DC. Hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med 1990; 323: 1401–1405.

49. Saeger W. Histopathological classification of adrenal tumors. Eur J Clin Invest 2000; 30 (Suppl 3): 58–62.

50. Saunders BD, Doherty GM. Laparoscopic adrenalectomy for malignant disease. Lancet Oncol 2004; 5: 718–726.

51. Schulte KM, Mengel M, Heinze M et al. Complete sequencing and messenger ribonucleic acid expression analysis of the MEN 1 gene in adrenal cancer. J Clin Endocrinol Metab 2000; 85: 441–448.

52. Soon PSH, McDonald KL, Robinson BG et al. Molecular markers and pathogenesis of adrenocortical cancer. Oncologist 2008; 13: 548–561.

53. Soreide JA, Braband K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970–1984. World J Surg 1992; 16: 663–667.

54. Stojadinovic A, Brennan MF, Hoos A et al. Adrenocortical adenoma and carcinoma: histopathological and molecular comparative analysis. Mod Pathol 2003; 16: 742–751.

55. Tissier F, Cavard C, Groussin L et al. Mutations of beta‑catenin in adrenocortical tumors: activation of the Wnt signalling pathway is a frequent event in both benign and malignant adrenocortical tumours. Cancer Res 2005; 65: 7622–7627.

56. Venkatesh S, Hickey RC, Sellin RV et al. Adrenal cortical carcinoma. Cancer 1989; 64: 765–769.

57. Weber MM, Auernhammer CJ, Kiess W et al. Insulin‑like growth factor receptors in normal and tumorous adult human adrenocortical glands. Eur J Endocrinol 1997; 136: 296–303.

58. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol 1984; 8: 163–169.

59. Wiedemann HR. Tumors and hemihypertrophy associated with Wiedemann‑Beckwith syndrome. Eur J Pediatr 1983; 141: 129.

60. Wieneke JA, Thompson LDR, Heffess CS. Adrenal cortical neoplasms in the pediatric population. A clinical and immunophenotypic analysis of 83 patients. Am J Surg Pathol 2003; 27: 867–881.

61. Wood BJ, Abraham J, Hvizda JL et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer 2003; 97: 554–560.

62. Libé R, Fratticci A, Bertherat J. Adrenocortical cancer: pathophysiology and clinical management. Endocrine-Related Cancer 2007; 11: 13–28.